

NEW ZEALAND KING SALMON INVESTMENTS LIMITED AND SUBSIDIARIES

INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 31 JULY 2021

1H22

CONTENTS FOR THE SIX MONTHS ENDED 31 JULY 2021

	Page
Corporate directory	3
Consolidated statement of comprehensive income	4
Consolidated statement of financial position	5
Consolidated statement of changes in equity	6
Consolidated statement of cash flows	7
Notes to the consolidated financial statements	8 - 14

NEW ZEALAND KING SALMON INVESTMENTS LIMITED AND SUBSIDIARIES

CORPORATE DIRECTORY

BOARD OF DIRECTORS

John William Dudley Ryder Independent Non-Executive Chairman Grantley Bruce Rosewarne Chief Executive Officer and Managing Director Jack Lee Porus Non-Executive Director Paul James Steere Independent Non-Executive Director Lai Po Sing Non-Executive Director Chiong Yong Tiong Non-Executive Director Catriona Macleod Independent Non-Executive Director

Audit and Finance Committee

Paul Steere (Chair) John Ryder Jack Porus (Appointed 26 August 2020)

Nominations and Remuneration Committee Paul Steere (Chair) Jack Porus

Health, Safety and Risk Committee Catriona Macleod (Chair) Chiong Yong Tiong

BANKERS

The Bank of New Zealand Deloitte Centre Level 6. 80 Queen Street

Auckland New Zealand

AUDITOR

Ernst & Young (EY) Level 4, 93 Cambridge Terrace Christchurch New Zealand

LAWYERS

Chapman Tripp Level 34, PwC Tower 15 Customs Street Auckland New Zealand

Gascoigne Wicks 79 High Street Blenheim New Zealand

Duncan Cotterill

197 Bridge Street Nelson New Zealand

NEW ZEALAND KING SALMON INVESTMENTS LIMITED

Ticker: NZK Listed on the NZX Main Board and as a foreign Exempt Listing on the ASX NZ Company number: 2161790

Registered Office

93 Beatty Street Annesbrook Nelson New Zealand

Postal Address PO Box 1180 Nelson 7040 New Zealand

Telephone +64 3 548 5714

Website www.kingsalmon.co.nz

Investor Relations investor@kingsalmon.co.nz

SHARE REGISTRY

Computershare Investor Services Limited Level 2, 159 Hurstmere Road Takapuna Auckland 0622 New Zealand +64 9 488 8777 enquiry@computershare.co.nz

Computershare Investor Services Pty Limited Yarra Fall 452 Johnston Street Abbotsford VIC 3001 Australia +61 3 9415 4083 enquiry@computershare.co.nz

INTERIM CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 31 JULY 2021

		UNAUDITED	UNAUDITED
		31 July 2021	31 July 2020
	Note	\$000	\$000
Revenue from contracts with customers	5	80.095	67,016
Cost of goods sold including fair value uplift at point of harvest	5	(86,621)	(68,507)
Fair value gain on biological transformation	8	30,692	(00,307) 16,418
Freight costs to market	0	(11,286)	
-		<u> </u>	(7,373)
Gross profit		12,880	7,554
Other income		327	3,812
Sales, marketing and advertising expenses		(6,480)	(5,792)
Distribution overheads		(2,800)	(2,130)
Corporate expenses		(4,939)	(5,072)
Other expenses		(102)	(33)
Earnings before interest, tax, depreciation and amortisation		(1,114)	(1,661)
Description and encertication surrouse		(5.170)	(5.000)
Depreciation and amortisation expense		(5,170)	(5,062)
Finance income		16	2
Finance expenses		(1,186)	(995)
(Loss) / Profit before tax		(7,454)	(7,716)
Income tax credit / (expense)		1,858	2,091
(Loss) / Profit after tax		(5,596)	(5,625)
Other comprehensive income			
Other comprehensive income that may be reclassified to profit or loss in	subsequent periods:		
Exchange differences on translation of foreign operations	subsequent perious.	(82)	(33)
Movement on cash flow hedges		(3,601)	17,754
Income tax effect of movement on cash flow hedges		1,008	(4,971)
		-	
Net other comprehensive income/ (loss)		(2,675)	12,750
Total comprehensive income / (loss)		(8,271)	7,125
		UNAUDITED	UNAUDITED
Earnings per share		31 July 2021	31 July 2020

Earnings per share		<u>31 J</u>	uly 2021	31 J	uly 2020
Basic earnings per share	6	\$	(0.04)	\$	(0.04)
Diluted earnings per share	6	\$	(0.04)	\$	(0.04)

The above interim consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 JULY 2021

1

ASSETS Current assets Cash and cash equivalents Trade and other receivables nventories	Note	\$000	\$00
Cash and cash equivalents Frade and other receivables nventories		0.007	
Trade and other receivables nventories			0.17
nventories		2,927	3,47
		15,559	16,18
	7	43,363	42,48
Biological assets	8	79,288	69,58
Derivative financial assets	11	2,969	5,41
Total current assets		144,106	137,15
Non-current assets			00.74
Property, plant and equipment		63,072	60,71
Biological assets	8	14,265	18,60
Derivative financial assets	11	1,649	16,35
ntangible assets		9,532	9,12
Right-of-use assets	9	6,333	6,81
Goodwill		39,255	39,25
Total non-current assets		134,106	150,86
TOTAL ASSETS		278,212	288,01
LIABILITIES			
Current liabilities			
Trade and other payables		25,620	18,59
Employee benefits		3,253	2,85
Borrowings	10	1,508	3,02
Lease liabilities		1,643	1,58
Other financial liabilities	14	233	23
Derivative financial liabilities	11	1,361	1,64
Taxation payable		941	5,07
Total current liabilities		34,559	33,01
Non-current liabilities			
Employee benefits		650	69
Borrowings	10	39,250	39,25
Lease liabilities		4,848	5,38
Deferred tax liabilities		14,130	16,92
Derivative financial liabilities	11	438	20
Total non-current liabilities		59,316	62,46
TOTAL LIABILITIES		93,875	95,47
NET ASSETS		184,337	192,54
EQUITY			
	13	122,606	122,60
Share capital	10	15,676	18,28
Reserves		46,055	51,65
Retained earnings			
TOTAL EQUITY		184,337	192,54
Net tangible assets per share		• • • • •	•
Net tangible assets per share		\$ 0.98	\$ 1.0
The above interim consolidated statement of financial position should be re	ead in conjunction	with the accompanyi	ng notes.
For and on behalf of the Board, who authorised the issue of these fin	ancial statements	on 29 September 2	2021
StA.			и — ССолинания и — К
Director Director	0'	-	

29 September 2021

Director 29 September 2021

INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 31 JULY 2021

		Foreign Currency	S	hare Based		
	Share	Translation	Hedge	Payment	Retained	Total
	Capital	Reserve	Reserve	Reserve	Earnings	Equity
UNAUDITED	\$000	\$000	\$000	\$000	\$000	\$000
Balance as at 1 February 2021	122,606	(1,162)	18,474	974	51,651	192,543
Profit / (loss) for the period	-	-	-	-	(5,596)	(5,596)
Other comprehensive income/(loss)	-	(82)	(2,593)	-	-	(2,675)
Total comprehensive income/(loss) for the period	-	(82)	(2,593)	-	(5,596)	(8,271)
Share based payment expense	-	-	-	65	-	65
Balance as at 31 July 2021	122,606	(1,244)	15,881	1,039	46,055	184,337
UNAUDITED						
Balance as at 1 February 2020	122,606	(564)	(3,487)	775	65,798	185,128
Profit / (loss) for the period	-	-	-	-	(5,625)	(5,625)
Other comprehensive income/(loss)	-	(33)	12,783	-		12,750
Total comprehensive income/(loss) for the period	-	(33)	12,783	-	(5,625)	7,125
Dividends paid - ordinary	-	-	-	-	(2,602)	(2,602)
Share based payment expense	-	-	-	102	-	102
Balance as at 31 July 2020	122,606	(597)	9,296	877	57,571	189,753

The above interim consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 31 JULY 2021

	UNAUDITED 31 July 2021 \$000	UNAUDITED 31 July 2020 \$000
	· · · · ·	· · · ·
Operating activities		
Receipts from customers	80,385	72,141
Payments to suppliers	(59,303)	(49,944)
Payments to employees	(21,087)	(21,123)
Interest received	16	2
Interest paid	(760)	(658)
Insurance and settlement income	-	3
Government grants received	285	3,869
Proceeds from foreign currency forward contracts closed early	13,495	-
Income tax paid	(4,058)	320
Net cash flows (used in) / from operating activities	8,973	4,610
Investing activities		
Proceeds from sale of property, plant and equipment	8	9
Purchase of property, plant and equipment	(6,440)	(7,253)
Purchase of intangible assets	(747)	(346)
Net cash flow (used in) / from investing activities	(7,179)	(7,590)
Financing activities		
Proceeds from borrowings	72,000	86,084
Repayment of borrowings	(73,516)	(78,070)
Gross proceeds from share issue	-	11
Dividends paid	-	(2,602)
Payment of lease liabilities	(852)	(805)
Net cash flows (used in) / from financing activities	(2,368)	4,618
Net increase / (decrease) in cash and cash equivalents	(574)	1,638
Net foreign exchange difference	22	(33)
Cash and cash equivalents at 1 February	3,479	3,730
Cash and cash equivalents at 31 July	2,927	5,335

The above interim consolidated statement of cash flows should be read in conjunction with the accompanying notes.

FOR THE SIX MONTHS ENDED 31 JULY 2021

1. CORPORATE INFORMATION

The interim financial statements of New Zealand King Salmon Investments Limited (the Company) and its subsidiaries (together the Group) for the six months ended 31 July 2021 were authorised by the Directors on 29 September 2021.

New Zealand King Salmon Investments Limited is a profit-orientated company incorporated and domiciled in New Zealand. The Company is registered under the Companies Act 1993 and listed on the NZX Main Board ("NZX") and the Australian Securities Exchange ("ASX"). The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013.

The interim consolidated financial statements are for the six months ended 31 July 2021 and have been prepared in accordance with NZ GAAP.

The Group is principally engaged in the farming, processing and sale of premium salmon products.

2. BASIS OF PREPARATION

a. Statement of compliance

The interim consolidated financial statements for the six months ended 31 July 2021 have been prepared in accordance with NZ IAS 34 - Interim Financial Reporting and IAS 34 Interim Financial Reporting, and should be read in conjunction with the annual financial statements as at 31 January 2021 which were prepared in accordance with New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and International Financial Reporting Standards (IFRS).

The interim consolidated financial statements for the six months ended 31 July 2021 are unaudited. Comparative information for the interim consolidated statement of financial position is at 31 January 2021 and is audited. Comparative information for the interim consolidated statement of comprehensive income, statement of interim consolidated changes in equity and interim consolidated statement of cash flows is for the comparative six month period 31 July 2020 and is unaudited. Comparative information are not what was previously reported due to the change in balance date.

b. Basis of measurement

The accounting policies adopted in the interim financial statements are consistent with those applied in the annual financial statements as at 31 January 2021.

The consolidated financial statements are presented in New Zealand dollars and all values are rounded to the nearest thousand (\$000), except when otherwise indicated.

c. Significant accounting judgements, estimates and assumptions

Management have applied the same principles and used the same key sources of estimation in the preparation of the interim financial statements as those applied in the consolidated financial statements for the period ended 31 January 2021.

d. Covid-19

While the impacts of the Covid-19 pandemic have continued to manifest during the reporting period, there remains some uncertainty over the ongoing impact. This uncertainty is reflected in the Group's estimates of the net realisable value of inventory. The net realisable value estimates the obsolescence and unmarketable items at the end of the reporting period based on assumptions of future demand within a specific time horizon.

3. SEASONALITY

The Group's business is seasonal with higher sales in the summer months and higher mortality rates are typically highest in the January to April period due to higher water temperatures at that time. This does impact on month to month profitability.

4. NEW STANDARDS ADOPTED AND STANDARDS ISSUED NOT YET ADOPTED

a. New standards adopted

There have been no new standards adopted during the 6 months to 31 July 2021.

b. New standards not yet adopted

Following recent IFRIC decision on accounting for cloud computing costs, the Company is still reviewing potential impact and will have the review finalised in time for its full year end financial statements as at 31 January 2022.

FOR THE SIX MONTHS ENDED 31 JULY 2021

5. SEGMENT INFORMATION

Segment results

The Group's strategy is to maximise longer term sales and overall margins by focusing on branded, premium priced and differentiated sales across its range of markets, channels and customers. The operating results of the whole business are monitored for the purpose of making decisions about resource allocating and performance. Accordingly, the Group is considered to consist of one operating segment.

Segment performance - Refer also Note 15 for detail of disaggregation of revenue by product, brand and geographical area.

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
	\$000	\$000
Revenue	80,095	67,016
Segment EBITDA	(1,114)	(1,661)
	UNAUDITED	UNAUDITED
Segment EBITDA reconciles to profit / (loss) before income tax as follows:	31 July 2021	31 July 2020
	\$000	\$000
Segment EBITDA	(1,114)	(1,661)
Depreciation, amortisation and impairment	(5,170)	(5,062)
Net finance costs	(1,170)	(993)
Group profit / (loss) before tax	(7,454)	(7,716)

6. EARNINGS PER SHARE

Basic earnings per share amounts are calculated by dividing the profit for the year attributable to shareholders of the Company by the weighted average number of ordinary shares on issue during the year. Diluted earnings per share assumes conversion of all potential ordinary shares in determining the weighted average number of ordinary shares on issue.

Earnings per share	UNAUDITED 31 July 2021 \$000		UNAUDITED 31 July 2020 \$000
Profit / (loss) attributable to ordinary equity holders	(5,596)		(5,625)
	# of Shares 000		# of Shares 000
Weighted average number of ordinary shares for diluted earnings per share	138,986		138,986
Basic earnings per share Diluted earnings per share	\$ (0.04) \$ (0.04)	\$ \$	(0.04) (0.04)

7. INVENTORIES

	UNAUDITED	AUDITED
	31 July 2021	31 January 2021
Inventories	\$000	\$000
Raw materials	16,563	11,853
Work in progress	1,935	2,748
Finished goods	24,865	27,888
Total inventories	43,363	42,489

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
Amount of inventories recognised as an expense in the statement of comprehensive income	\$000	\$000
Cost of inventories recognised as an expense	87,590	68,300
Movement in net realisable value provision	(969)	207
Total cost of goods sold including fair value uplift at point of harvest	86,621	68,507

The cost of inventories recognised as an expense for the period ended 31 July 2021 includes a fair value uplift at point of harvest of \$23,348k, (31 July 2020: \$24,301k). This cost is included in cost of goods sold in the Statement of Comprehensive Income.

8. BIOLOGICAL ASSETS

The Group has three hatcheries in the South Island and nine operational marine salmon farms in the Marlborough Sounds. The fish livestock typically grow for up to 31 months before harvest.

UNAUDITED	Cost	Fair value	Total
Biological assets	\$000	\$000	\$000
As at 1 February 2021	55,025	33,163	88,188
Increase due to biological transformation ¹	42,189	25,947	68,136
Decrease due to harvest ²	(33,849)	(23,280)	(57,129)
Decrease due to mortality ³	(10,387)	-	(10,387)
Changes in fair value ⁴	-	4,745	4,745
As at 31 July 2021	52,978	40,575	93,553

¹ Biological transformation fair value is impacted by volume increases (net of mortalities) and fish size at reporting date relative to the target harvest weight of 4 kgs (proportional recognition).
² Harvested fair value is included under cost of goods sold in the statement of comprehensive income and is calculated by multiplying the current years harvest (biomass) by the prior years expected gross margin per kg (recognised at 100%).

³ Mortality cost is expensed directly to the statement of comprehensive income in the period which it occurs.

⁴ Changes in fair value are impacted by movements in margin primarily being changes in sales price and costs to sell (fish cost, harvest, processing and freight to market).

FOR THE SIX MONTHS ENDED 31 JULY 2021 BIOLOGICAL ASSETS (CONTINUED)

BIOLOGICAL ASSETS (CONTINUED)			
UNAUDITED	Cost	Fair value	Total
Biological assets	\$000	\$000	\$000
As at 1 February 2020	53,856	50,178	104,034
Increase due to biological transformation ¹	40,486	17,805	58,291
Decrease due to harvest ²	(30,399)	(28,678)	(59,077)
Decrease due to mortality ³	(8,274)	-	(8,274)
Changes in fair value ⁴	-	(1,387)	(1,387)
As at 31 July 2020	55,669	37,918	93,587

¹ Biological transformation fair value is impacted by volume increases (net of mortalities) and fish size at reporting date relative to the target harvest weight of 4 kgs (proportional recognition).
² Harvested fair value is included under cost of goods sold in the statement of comprehensive income and is calculated by multiplying the current years harvest (biomass) by the prior years expected gross margin per kg (recognised at 100%).

³ Mortality cost is expensed directly to the statement of comprehensive income in the period which it occurs.

⁴ Changes in fair value are impacted by movements in margin primarily being changes in sales price and costs to sell (fish cost, harvest, processing and freight to market).

AUDITED	Cost	Fair value	Total
Biological assets	\$000	\$000	\$000
As at 1 July 2020	53,704	38,674	92,379
Increase due to biological transformation ¹	51,807	33,726	85,533
Decrease due to harvest ²	(42,233)	(34,860)	(77,093)
Decrease due to mortality ³	(8,253)	-	(8,253)
Changes in fair value ⁴	-	(4,377)	(4,377)
As at 31 January 2021	55,025	33,163	88,188

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
Fair value gain / (loss) recognised in profit and loss	\$000	\$000
Gain arising from growth of biological assets	25,947	17,805
Movement in fair value of biological assets	4,745	(1,387)
Total fair value gain on biological transformation	30,692	16,418

	UNAUDITED 31 July 2021	UNAUDITED 31 July 2020
Harvested biomass	tonnes	tonnes
Total live weight harvested for the period	3,903	4,070
	UNAUDITED 31 July 2021	AUDITED 31 January 2021
Estimated closing biomass	tonnes	tonnes
Closing fresh water stocks	138	173
Closing seawater stocks	6,335	6,691
Total estimated closing biomass live weight	6,473	6,864

Fair value measurement

Measurement of fair value is performed using a fair value model. The method of valuation therefore falls into level 3 of the fair value hierarchy as the inputs are unobservable inputs.

The valuation of biological assets is carried out separately for each site at a brood and strategy level. Estimated actual cost up to the date of harvest per site is used to measure the expected margin at the time the fish is defined as ready for harvest, being 4.0kg live weight. Selling price is estimated at balance date based on the most relevant future market price at expected harvest date. The expected gross margin is recognised proportionately based on average biomass at reporting date. Fair value measurement commences at the date of transfer to sea water as this is considered the point at which the fish commence their grow out cycle.

Fair value risk and sensitivity

The Group is exposed to financial risks relating to the production of salmon stock including increasing climate change volatility, climatic events, disease and contamination of water space.

The Group seeks to produce and market the highest quality salmon products. Extensive monitoring and benchmarking is carried out to provide optimum conditions and diets to maximise fish performance during the grow out cycle. Sales are maintained in a range of brands, products and markets to maximise returns from the quality mix of fish harvested. The Group has insurance to cover some of the risks relating to the livestock.

The estimated unrealised fair value gain from cost at 31 July 2021 has increased from the prior period end (31 January 2021) estimation due to core sales volumes broadly returning to pre-Covid levels as expected. While price increases have been implemented, some costs of producing and shipping product still remain higher than normal. Changes in these assumptions will impact the fair value calculation. The realised profit which is achieved on the sale of inventory will differ from the calculations of fair value of biological assets because of changes in key factors such as the final market destinations and product mix of inventory sold, changes in price, foreign exchange rates, harvest weight, growth rates, mortality, cost levels and differences in harvested fish quality.

Leaving all other variables constant a 15% increase/decrease in average future sales prices would have increased/decreased the fair value of biological assets on hand and profit before tax by \$19.5m (31 January 2021: 15% increase / decrease \$18.3m) (excludes the impact of finished goods), while a 15% increase/decrease in estimated future harvest volume would increase/decrease the fair value of biological assets on hand and profit before tax by \$5.5m (31 January 2021: 15% increase / decrease \$2.1m).

A 15% increase/decrease in estimated costs to sell would decrease/increase the fair value of biological assets on hand at balance date and profit before tax by \$14.5m (31 January 2021: 15% increase / decrease \$15m). Changes in fish health and environmental factors may affect the quality of harvested fish, which may be reflected in realised profit via both achieved sales price and production costs.

FOR THE SIX MONTHS ENDED 31 JULY 2021

q

RIGHT-OF-USE ASSETS					
	Land &	Motor	Plant &	UNAUDITED	AUDITED
	Building	Vehicles	Equipment	31 July 2021	31 January 2021
UNAUDITED	000	000	000	\$000	\$000
Carrying amount at 01 February or 01 July	5,589	354	867	6,810	4,581
Additions	-	235	-	235	2,413
Remeasurement	233	7	-	240	796
Depreciation for the period	(602)	(113)	(238)	(953)	(980)
Carrying amount as at 31 July or 31 January	5,220	483	629	6,333	6,810
Cost	7,037	918	1,597	9,552	9,227
Accumulated Depreciation	(1,817)	(435)	(968)	(3,219)	(2,417)
Carrying amount as at 31 July or 31 January	5,220	483	629	6,333	6,810

10. INTEREST BEARING LOANS AND BORROWINGS

INTEREST BEARING LOANS AND BORROWINGS	UNAUDITED	AUDITED	
	31 July 2021	31 January 2021	
Current interest bearing loans and borrowings	\$000	\$000	
Secured bank loans	750	750	
Other borrowings	758	2,274	
Total current interest bearing loans and borrowings	1,508	3,024	
Non-current interest bearing loans and borrowings			
Secured bank loans	39,250	39,250	
Total non-current interest bearing loans and borrowings	39,250	39,250	

The Company has facilities with BNZ for \$60m, secured by a general security deed over the assets of the Group. The expiry date of facility A of \$20m is 18 October 2022, facility B of \$20m expires on 18 October 2023, and facility C of \$20m expires on 18 October 2024. At balance date \$20m of facility A was drawn, \$15m of facility B was drawn and facility C was undrawn (as at 31 January 2021 total: \$35m). The Company also secured a Business Finance Scheme Loan via BNZ for \$5m (expiry October 2025) that arose from the Government providing financial assistance following the pandemic virus Covid-19. At balance date the Business Finance Scheme loan was fully drawn at \$5m.

11. FAIR VALUE OF FINANCIAL INSTRUMENTS

The carrying value of cash and short term deposits, trade receivables, trade payables and other current liabilities is considered a reasonable approximation to their fair value due to the short term maturities of these instruments.

The carrying value of the BNZ loan drawing of \$40m is considered a reasonable approximation of its fair value due to the short term maturities of the drawings. The Group has the discretion to roll these short term drawings out within facility A (\$20m) to 18 Oct 2022, and within facility B (\$20m) to 18 Oct 2023.

The following financial instruments of the Oreum are parried at fair values

The following financial instruments of the Group are carried at fair value:	UNAUDITED	AUDITED
	31 July 2021	31 January 2021
Current derivative financial assets	\$000	\$000
Forward exchange contracts	2,410	4,509
Foreign exchange options	559	904
Total Current derivative financial assets	2,969	5,413
Non-current derivative financial assets		
Forward exchange contracts	1,057	15,454
Foreign exchange options	592	900
Total Non-current derivative financial assets	1,649	16,354
Current derivative financial liabilities		
Forward exchange contracts	254	94
Foreign exchange options	40	61
Interest rate swaps	1,067	1,491
Total Current derivative financial liabilities	1,361	1,646
Non-current derivative financial liabilities		
Forward exchange contracts	226	18
Foreign exchange options	212	186
Interest rate swaps	-	-
Total non-current derivative financial liabilities	438	204

Valuation methods

Financial instruments have been categorised into the following hierarchy and valued according to the following definitions, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1: Quoted prices in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices)

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs)

All derivative financial instruments for which a fair value is recognised have been categorised within level 2 of the fair value hierarchy. Industry experts have provided the fair values for all derivatives based on an industry standard model. There were no transfers between Level 1 and Level 2 during the period ended 31 July 2021.

AUDITED

FOR THE SIX MONTHS ENDED 31 JULY 2021

12. COMMITMENTS AND CONTINGENCIES

UNAUDITED

Capital commitments

The Group has entered into agreements to purchase plant and equipment. As at 31 July 2021 the total commitment is \$4,202k (31 January 2021: \$1,629k).

The Group has a contingent liability at 31 July 2021 of \$772k in respect of a fish transport contract requiring the Group to purchase three bulk tankers (including modifications made in 2018 and 2020), should the fish transport contract be terminated early (31 January 2021: \$826k).

Guarantees

The group has three guarantee facilities at 31 July 2021 totalling \$131k (31 January 2021: \$115k).

13. CAPITAL AND RESERVES

	UNAUDITED	AUDITED
Share capital	31 July 2021	31 January 2021
Issued shares	000	000
Ordinary shares	138,986	138,986
Total issued shares	138,986	138,986
	1.1 1 1	

Ordinary shares are fully paid with no par value. Each ordinary share has an equal right to vote, to participate in dividends and to share in any surplus on winding up of the Company. No dividend was declared nor paid during the 6 months to 31 July 2021 (6 months to 31 July 2020: fully imputed interim dividend of \$0.02 per share was paid on 20 March 2020).

	# of Shares		Share	Capital
	UNAUDITED	AUDITED	UNAUDITED	AUDITED
	31 July 2021	31 January 2021	31 July 2021	31 January 2021
Movement in ordinary share capital	000	000	\$000	\$000
As at 1 February or 1 July	138,986	138,986	122,606	122,606
Share issue for employee share scheme	-	-	-	-
Share issue recognised on repayment of employee loans	-	-	-	-
As at 31 July or 31 January	138,986	138,986	122,606	122,606
Shares held as treasury stock	313	232		
Total shares outstanding at 31 July or 31 January	138,673	138,754		

Reserves

Foreign currency translation reserve

The foreign currency translation reserve is used to record exchange difference arising from the translation of the financial statements of the foreign subsidiary.

Hedge reserve

The hedge reserve represents the unrealised gains and losses on interest rate swaps and foreign currency forward contracts that the Group has taken out in order to mitigate interest rate and foreign currency risks, net of deferred tax.

Retained earnings

Retained earnings represents the profits retained in the business.

Share based payment reserve

The share based payment reserve relates to one long term incentive (LTI) scheme and two employee share ownership schemes. All of these schemes involve the Company making interest-free limited recourse loans to selected personnel to acquire shares in the Company. The employees must remain in employment for the duration of the vesting or escrow periods before the employees receive the full benefit of share ownership subsequent to repayment of the loan balance remaining at time of vesting.

		31 January					
		2021 shares	New shares	Shares	Shares		31 July 2021
		not yet	issued to	allocated from	forfeited to		shares not yet
Share scheme	Grant date	vested	custodian	treasury stock	treasury stock	Shares vested	vested
		000	000	000	000	000	000
LTI 2018	27/09/2018	271	-	-	(43)	-	228
LTI 2019	5/11/2019	251	-	-	(38)	-	213
Total share scher	ne	522		-	(81)	-	441

* Fully vested in current year

The estimated value of share options was determined using the Black-Scholes pricing calculator and is being amortised over the restrictive periods. The option cost is treated as an employee expense with the corresponding credit included in the share based payment reserve. The inputs into the option pricing valuation model are the share price of the Group at time of allocation and the compounded risk free interest rate.

Share allocation price for share schemes

Share scheme	Employee Group 1	Employee Group 2	Employee Group 3	Employee Group 4
LTI 2018	\$1.30	\$1.95	\$2.78	-
LTI 2019	\$1.41	\$2.13	-	\$2.20

FOR THE SIX MONTHS ENDED 31 JULY 2021

14. RELATED PARTY DISCLOSURES

Subsidiaries

New Zealand King Salmon Investments Limited has the following trading subsidiaries.

Subsidiary	Country of Incorporation	Equity Interest
The New Zealand King Salmon Co. Limited	New Zealand	100%
New Zealand King Salmon Exports Limited	New Zealand	100%
The New Zealand King Salmon Pty Limited	Australia	100%
New Zealand King Salmon USA Incorporated	United States of America	100%

The principal activity of The New Zealand King Salmon Co. Ltd is the farming and processing of salmon. The activity of New Zealand King Salmon Exports Limited, The New Zealand King Salmon Pty Limited, and New Zealand King Salmon USA Incorporated is the distribution of salmon.

At balance date Oregon Group Limited owned 40.02% (31 January 2021: 40.02%) and China Resources Ng Fung Limited owned 9.96% (31 January 2021: 9.96%) of the shares in New Zealand King Salmon Investments Limited.

Transactions with related parties

Sales to and purchases from related parties are made in arm's length transactions both at normal market prices and on normal commercial terms. The following provides the total amount of transactions that were entered into with related parties for the relevant financial year:

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
Related party payments	\$000	\$000
Goods and services purchased from other related parties	186	181
Total related party payments	186	181
Related party sales		
Goods and services sold to related parties	-	-
Total related party sales	-	-

Sales to and purchases from related parties are made in arm's length transactions, both at normal market prices and on normal commercial terms.

	UNAUDITED	AUDITED
Amounts owing to related parties	31 July 2021	31 January 2021
Current amounts owing to related parties	\$000	\$000
Other amounts owing to related parties	(233)	(233)
Total current amounts owing to related parties	(233)	(233)

	UNAUDITED	AUDITED
	31 July 2021	31 January 2021
Amounts owing by related parties	\$000	\$000
Amounts owing by related parties	-	3
Total amounts owing by related parties	-	3
	UNAUDITED	UNAUDITED
Compensation of key management personnel of the Group	31 July 2021	31 July 2020
Key management personnel compensation	\$000	\$000
Short-term employee benefits	954	878
Share based payment expense	81	121
Post employment pension and medical benefits	78	30
Total key management personnel compensation	1,113	1,029

FOR THE SIX MONTHS ENDED 31 JULY 2021 15. DISAGGREGATION OF REVENUE

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
Revenue by Product Group	\$000	\$000
Whole Fish	40,055	31,506
Fillets, Steaks & Portions	17,142	13,342
Wood Roasted	6,245	5,779
Cold Smoked	12,013	11,927
Other	4,640	4,462
Total	80,095	67,016

Revenue by Brand	UNAUDITED 31 July 2021 \$000	UNAUDITED 31 July 2020 \$000
Ōra King	26,989	24,917
New Zealand King Salmon	32,323	21,907
Regal	15,127	15,307
Southern Ocean	4,479	3,870
Omega Plus	1,177	1,015
Total	80,095	67,016

	UNAUDITED	UNAUDITED
	31 July 2021	31 July 2020
Revenue by Market	\$000	\$000
New Zealand	33,294	28,806
North America	29,778	25,880
Australia	5,076	3,930
Japan	6,032	1,926
China	366	1,204
Europe	2,543	1,547
Other	3,006	3,723
Total revenue	80,095	67,016

Sales net of settlement discounts to two major customers for the 6 months period ended 31 July 2021 totalled \$8.2m or 10.27% of total gross revenue, (6 months to 31 July 2020 one major customer totalled \$8.6m or 12.92% of total gross revenue).

16. EVENTS AFTER BALANCE DATE

Covid-19

Following the confirmation of community transmission of the Covid-19 delta variant on 17 August 2021, the Government announced a range of alert level lockdowns across New Zealand. Subsequent announcements were also made and at date of signing these financial statements the Auckland region is in alert level 3 with the rest of the country in alert level 2. As noted in Note 2.d. the forecast assumptions in relation to the net realisable value remains reasonable.

Open ocean consent

A hearing date has been established for the open ocean farming consent application in October 2021.

Dividend

No final dividend was declared in respect of the 6 months ended 31 July 2021 (7 month period to 31 January 2021: Nil).